Market Overview

UPDATE: Dawson James Initiates Galena Biopharma at Market Outperform

Share:
Related GALE
Mid-Afternoon Market Update: Walker & Dunlop Gains After Q4 Results; SPS Commerce Shares Tumble
20 Biggest Mid-Day Losers For Wednesday

Dawson James initiated coverage on Galena Biopharma (NASDAQ: GALE) with a Buy rating and a $3 price target.

Dawson James commented, "We believe investors have yet to fully appreciate NeuVax's clinical potential and chance of success in the Phase III PRESENT study currently underway. After assessing the NeuVax Phase II data on hand and speaking with Company management, we believe Galena has managed to implement several key insights gained from prior trials into in the Phase III PRESENT study, ignificantly improving its likelihood of success."

Galena Biopharma closed at $1.68 on Monday.

Latest Ratings for GALE

DateFirmActionFromTo
Feb 2017FBR CapitalDowngradesOutperformMarket Weight
Feb 2017Maxim GroupDowngradesBuyHold
Jun 2016Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: Dawson James iAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GALE)

View Comments and Join the Discussion!